About the IOV-LUN-202 trial
IOV-LUN-202 is a global clinical trial currently enrolling people with NSCLC that has progressed (on previous chemoimmuntherapy) and is metastatic (has spread to a different part of the body).
The trial is studying lifileucel, an investigational TIL cell therapy.
IOV-LUN-202 will assess the safety of lifileucel and its potential to:
- Reduce tumor size
- Slow tumor growth
- Eliminate tumors that show up on scans
- Extend patients’ lives without their cancer worsening
Patients may be eligible to participate in this trial if:
- Their cancer did not respond to previous chemotherapy and immunotherapy
- Their heart is working well and is pumping more than 45% of the blood expected with each beat (LVEF >45%)
- Their lungs are working well and moving air the way they should
- They have at least 1 resectable tumor (can be removed by surgery) and 1 tumor that can be tracked on scans
Here is what patients can expect in the trial
Patients who qualify will be put into 1 of the following study groups:
Group 1
PD-L1* levels <1% before immunotherapy
Group 2
PD-L1 levels >1% before immunotherapy
Group 3
Patients, regardless of PD-L1 level, who are unable to undergo a surgical procedure to obtain TIL but are able to tolerate a core biopsy procedure
*A protein, found on tumor cells and some normal cells, that affects the immune system.
PD-L1=programmed death ligand 1.
Find a trial location
See the list of active trial locations below.
Get started
This website is intended for a U.S. audience. TIL cell therapy is not yet approved by any regulatory or health agency for the investigational uses described in this website. This website is for educational purposes only and is not intended to replace discussions with a healthcare professional.
